Minneapolis, MNNCT03579875Now EnrollingIRB Ready

Fanconi Anemia Clinical Trial in Minneapolis, MN

Access cutting-edge fanconi anemia treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Sponsored by Masonic Cancer Center, University of Minnesota

Quick Self-Assessment

See if you qualify for this Minneapolis location

Preparing your pre-screening questions…

Expert Care in Minneapolis

Access fanconi anemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related fanconi anemia treatment provided free

Apply for This Minneapolis Location

Check if you qualify for this fanconi anemia clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneapolis

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneapolis site if eligible
  4. 4Begin participation

About This Fanconi Anemia Study in Minneapolis

This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.

Sponsor: Masonic Cancer Center, University of Minnesota

Who Can Participate

Inclusion Criteria

For FA patients:
Diagnosis of Fanconi anemia
Age \<65 years of age
Has one of the following risk factors:
Severe aplastic anemia (SAA)
Myelodysplastic features
High risk genotype
Immunodeficiency associated with history of recurrent infections
Karnofsky performance status ≥ 70% if ≥ 16 years of age or Lansky play score ≥ 50% for patients \<16 years of age
Adequate pulmonary, cardiac and liver function
Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care For TBD patients: • Diagnosis of TBD
Age \<70 years of age
Has one of the following risk factors:
Severe aplastic anemia (SAA)
Myelodysplastic features
Karnofsky performance status ≥ 70% if ≥ 16 years of age or Lansky play score ≥ 50% for patients \<16 years of age
Adequate pulmonary, cardiac and liver function
Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care

Exclusion Criteria

Pregnant or breastfeeding as the treatment used in this study are Pregnancy Category D. Females of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days of study registration
Active, uncontrolled infection within 1 week prior to starting study therapy
Malignant solid tumor cancer within previous 2 years Donor Selection (Inclusion Criteria): meets one of the following match criteria:
an HLA-A, B, DRB1 matched sibling donor (matched sibling)
an HLA-A, B, DRB1 matched related donor (other than sibling)
a related donor mismatched at 1 HLA-A, B, C and DRB1 antigen
7-8/8 HLA-A,B,C,DRB1 allele matched unrelated donor per current institutional guidelines Patients and donors are typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. If a donor has been selected on the basis of HLA-A, B, C and DRB1 typing as above, preference will be made for donors matched at the HLA-C locus.
Body weight of at least 40 kilograms and at least 12 years of age
Willing and able to undergo mobilized peripheral blood apheresis
In general good health as determined by the medical provider
Adequate organ function defined as:
Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)
Hepatic: ALT \< 2 x upper limit of normal
Renal: serum creatinine \< 1.8 mg/dl
Performance of a donor infectious disease screen panel including CMV Antibody, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV 1/2 Antibody, HTLVA 1/2 Antibody, Treponema, and Trypanosoma Cruzi (T. Cruzi) plus HBV, HCV, WNV, HIV by nucleic acid testing (NAT); and screening for evidence of and risks factors for infection with Zika virus, or per current standard institutional donor screen - must be negative for HIV and active hepatitis B
Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of mobilization start
Voluntary written consent (parent/guardian and minor assent, if \< 18 years) prior to the performance of any research related procedure

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT03579875) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Fanconi Anemia Treatment Options in Minneapolis, MN

If you're searching for fanconi anemia treatment options in Minneapolis, MN, this clinical trial (NCT03579875) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced fanconi anemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all fanconi anemia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Minneapolis, MN

See all heart attack clinical trials recruiting in Minneapolis — not just this study.

Browse Heart Attack Trials in Minneapolis →

Browse More Trials by Condition

Heart Attack TrialsAnemia TrialsMyocardial Infarction TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Minneapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneapolis, MN